ASCO 2021: Updates in Genitourinary Cancers | Supplements And Featured Publications

This publication provides coverage of data in genitourinary cancers that were presented at the 2021 ASCO Annual Meeting.

Frontline Belzutifan Showcases Significant Clinical Activity in VHL-Associated RCC

June 09, 2021

The hypoxia-inducible factor-2 alpha inhibitor belzutifan maintained clinical efficacy with further follow-up in patients with Von-Hippel Lindau–associated renal cell carcinoma, as well as other VHL-associated neoplasms.

Cabozantinib Exposure Not Associated With PFS, But Is Linked With Higher AEs With Cabozantinib/Nivolumab in RCC

June 09, 2021

Cabozantinib exposure was not significantly associated with progression-free survival but appeared to predict high rates of palmar-plantar erythrodysesthesia and diarrhea in patients with advanced renal cell carcinoma treated with the frontline combination of cabozantinib and nivolumab.

Lenvatinib/Pembrolizumab Yields Survival Benefit in Advanced RCC Across IMDC Risk Groups

June 09, 2021

The addition of lenvatinib to pembrolizumab elicited a notable survival benefit and improved responses over single-agent sunitinib in patients with advanced renal cell carcinoma across evaluable International Metastatic RCC Database Consortium risk subgroups.

Pembrolizumab/Cabozantinib Combo Provides Benefit in mRCC

June 09, 2021

The combination of pembrolizumab and cabozantinib induced a response in more than half of patients with metastatic renal cell carcinoma at the recommended phase 2 dose with a manageable safety profile, meeting the primary end point of a phase 1/2 trial.

Frontline Avelumab Maintenance Improves OS Regardless of Primary Tumor Site, Advanced Disease Type in Advanced Urothelial Cancer

June 04, 2021

Avelumab as frontline maintenance plus best supportive care demonstrated a survival benefit compared with BSC alone across several previously unreported subgroups of patients with advanced urothelial cancer who have progressed on first-line platinum-containing chemotherapy.